Nuvectis Pharma (NVCT) to Release Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) is projected to release its earnings data before the market opens on Tuesday, March 4th. Analysts expect Nuvectis Pharma to post earnings of ($0.28) per share for the quarter.

Nuvectis Pharma Trading Down 3.0 %

Shares of NVCT stock opened at $7.36 on Tuesday. The stock has a market capitalization of $142.20 million, a P/E ratio of -6.34 and a beta of 0.22. Nuvectis Pharma has a 12 month low of $4.44 and a 12 month high of $12.10. The firm’s 50 day moving average is $6.14 and its 200 day moving average is $6.40.

Insider Transactions at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri acquired 17,000 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $4.70 per share, for a total transaction of $79,900.00. Following the acquisition, the insider now owns 2,612,000 shares of the company’s stock, valued at $12,276,400. This trade represents a 0.66 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders have purchased 261,500 shares of company stock valued at $1,300,825 in the last quarter. Insiders own 35.78% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.